This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Glenn Noronha, Ph.D., Vice President Of Research And Development, Sucampo Pharma Americas, LLC (Photo: Sucampo Pharmaceuticals, Inc.)

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that Glenn Noronha, Ph.D., has joined Sucampo Pharma Americas, LLC (SPA) as Vice President of Research and Development, reporting to Ryuji Ueno, M.D., Ph.D., Ph.D., Chairman, Chief Scientific Officer and Chief Executive Officer. He will assist with strengthening and leading Sucampo’s U.S. R&D functions. Dr. Noronha is responsible for the development of the overall product portfolio from research through approval.

Glenn Noronha, Ph.D., Vice President of Research and Development, Sucampo Pharma Americas, LLC (Phot ...

Glenn Noronha, Ph.D., Vice President of Research and Development, Sucampo Pharma Americas, LLC (Photo: Sucampo Pharmaceuticals, Inc.)

Dr. Noronha also was named to Sucampo's Global R&D Leadership Team, which is headed by Dr. Ueno, and includes: Taryn Joswick, Vice President, Clinical Development of SPA; Birgit Roerig, Ph.D., Vice President, Pharmacology and Toxicology at SPA; Peter Lichtlen, M.D., Ph.D., Senior Medical Officer and Vice President, European Operations, of Sucampo AG (SAG); Takashi Sekida, Ph.D., Vice President, Research Planning & Business Development, at Sucampo Pharma, Ltd. (SPL); and Gayle Dolecek, P.D., M.P.H., Executive Advisor, R&D Affairs, SPA. SPA, SAG and SPL are wholly-owned subsidiaries of SPI.

Dr. Ueno said, “We welcome Dr. Noronha to Sucampo and look forward to his contributions in strengthening our expertise, particularly in ophthalmology as we prepare for the launch of RESCULA. His extensive drug development experiences, from preclinical to clinical, and knowledge of ophthalmology, oncology, and immune and inflammatory mediated diseases will add great value to our R&D pipeline for new indications of our prostone-based products AMITIZA ® and RESCULA ®, as well as to other compounds based on our proprietary prostone technology. Additionally, Sucampo will benefit from his experience of taking research findings into the clinic.”

Dr. Noronha joins Sucampo from JW Theriac, Inc., a pharmaceutical company focused on new drug research and development, which he joined in July 2011 as Chief Scientific Officer, responsible for translational efforts in the oncology therapeutic area. At JW Theriac, he successfully identified and proposed opportunities for research and innovation along with the assessment of risks and technical hurdles. Prior to JW Theriac, Dr. Noronha had leadership roles in Retina Development at Alcon Laboratories, Inc., now part of Novartis, from November 2008 to July 2011, with global responsibilities for planning and executing all stages of retina development, including working with clinical, regulatory, scientific, non-clinical and technical colleagues for both small molecules and biologics. Previously, from June 2002 to July 2008, Dr. Noronha worked at TargeGen, Inc., now acquired by Sanofi-Aventis, and held several positions of increasing responsibility, among them Senior Scientist, Group Leader and Director. At TargeGen, he delivered three of the five small molecule candidates into development that were entered into clinical trials; one small molecule candidate resulted in successful phase 2 results. Dr. Noronha earned his Ph.D. in Organometallic Chemistry from Loyola University Chicago and conducted post-doctoral research at the University of California, Irvine in protein structural and bio-organic chemistry. Dr. Noronha is a member of the Association for Research in Vision and Ophthalmology (ARVO) and is named on 21 composition of matter and use patents for drugs in ophthalmology, oncology, immune and inflammatory diseases and in continuous glucose sensing. He is the author of more than 30 peer-reviewed articles and more than 70 scientific presentations at national and international forums.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones, which occur naturally in the human body as a result of enzymatic catalysis by 15-PGDH of eicosanoids and docosanoids, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo’s Chairman and CEO. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding CEO and currently Executive Advisor, International Business Development, and a member of the Board of Directors. For more information, please visit www.sucampo.com.

AMITIZA ® is a registered trademark of Sucampo AG. RESCULA ® is a registered trademark of R-Tech Ueno, Ltd, and has been licensed to Sucampo.

Sucampo Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the US and internationally and the exposure to litigation and/or regulatory actions.

Stock quotes in this article: SCMP 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs